Financial Performance & Strategic Aspirations - Novo Nordisk achieved sales growth of 18% (CER) in the first six months of 2025, with operating profit growth of 29% (CER)[11] - Obesity care sales reached DKK 38.8 billion, a 58% increase at CER, highlighting the strong performance in this therapeutic area[11] - Rare disease sales increased by 15% at CER, reaching DKK 9.5 billion[11] - The company returned DKK 36.5 billion to shareholders, demonstrating a commitment to attractive capital allocation[11] Market Dynamics & Key Products - In the US, the branded anti-obesity medication market experienced growth exceeding 160%[28] - International Operations saw sales growth of 19%, driven by GLP-1 Diabetes and Obesity care[33] - Total GLP-1 class market share in International Operations reached 71%[36] - Global diabetes and obesity unmet need is significant, with less than 1% of people with obesity globally treated with branded AOMs[44] Research & Development Highlights - Amycretin is advancing to phase 3 development based on successful phase 1b/2a trial results, showing significant body weight loss[49, 53] - Semaglutide 2.4 mg demonstrated a 20% reduction in MACE in the SELECT trial for people with overweight or obesity and established CVD[249]

Core Insights - Eli Lilly's diabetes drug Mounjaro demonstrated heart health benefits in a late-stage trial compared to Trulicity, meeting the study's primary goal of non-inferiority in treating Type 2 diabetes with cardiovascular disease [2][4] - Despite the positive results, Eli Lilly's shares fell 4% in premarket trading as the outcomes did not exceed some analysts' expectations for superiority over Trulicity [2][3] - The trial showed Mounjaro reduced the risk of cardiovascular death, heart attack, or stroke by 8% compared to Trulicity, with additional benefits including a 16% lower rate of all-cause mortality [4][5] Company Positioning - Eli Lilly believes the new data strengthens Mounjaro's position as the preferred choice for Type 2 diabetes patients, especially as Trulicity faces patent expiration in 2027 [3][10] - The company plans to submit heart health data to global regulators by the end of the year, potentially leading to approvals for Mounjaro's use in cardiovascular health by 2026 [11] Market Dynamics - Mounjaro's current approval already covers many patients with Type 2 diabetes who also have cardiovascular disease, as approximately 30% of these patients are affected [13] - Analysts suggest that even if Mounjaro shows similar heart health benefits as Trulicity, it may not significantly change prescribing behaviors among doctors [14][15] Clinical Insights - The trial was the longest and largest to date on tirzepatide, enrolling over 13,000 participants, and showed Mounjaro's advantages in cardiovascular measures and weight loss [4][16] - Some clinicians noted that the difference in all-cause mortality rates between Mounjaro and Trulicity is clinically significant, aiding in treatment decision-making [6][7] Competitive Landscape - Eli Lilly is solidifying its lead over Novo Nordisk in the growing market for diabetes and weight loss drugs, with both companies demonstrating additional health benefits of their products [10]

MannKind Jefferies Global Healthcare Conference June 5, 2025 © Copyright 2025. All rights reserved. MannKind Corporation. Cautionary Statement Statements in this presentation that are not statements of historical fact are forward- looking statements that involve risks and uncertainties. Words such as "believes", "anticipates", "plans", "expects", "intend", "will", "goal", "potential" and similar expressions are intended to identify forward-looking statements. These forward- looking statements are based upon ...

Analyst & Investor Day May 22, 2025 New York, New York 1 Welcome to Analyst & Investor Day Pravesh Khandelwal Vice President, Investor Relations 2 2 Forward-looking statements Safe Harbor Statement Regarding Forward-Looking Statements This presentation contains express or implied "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward-looking statements concern our current expectations regarding our future results ...